for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eagle Pharmaceuticals Inc

EGRX.OQ

Latest Trade

58.40USD

Change

0.06(+0.10%)

Volume

69,684

Today's Range

56.99

 - 

59.92

52 Week Range

36.10

 - 

64.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.34
Open
57.59
Volume
69,684
3M AVG Volume
3.10
Today's High
59.92
Today's Low
56.99
52 Week High
64.94
52 Week Low
36.10
Shares Out (MIL)
13.67
Market Cap (MIL)
844.75
Forward P/E
20.71
Dividend (Yield %)
--

Latest Developments

More

Eagle Pharma’s Japanese Licensing Partner Symbio Submits A New Drug Application For Treakisym Ready-To-Dilute Formulation

Eagle Pharmaceuticals Inc. Q2 Earnings Per Share $0.48

Eagle Pharma Expects Pivotal Breast Cancer Trial To Be Completed Within About 12 Months Of Commencing Enrollment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Industry

Biotechnology & Drugs

Contact Info

50 Tice Blvd Ste 315

+1.201.3265300

http://www.eagleus.com/

Executive Leadership

Michael Graves

Independent Chairman of the Board

David M. Pernock

President, Chief Operating Officer

Scott L. Tarriff

Chief Executive Officer, Director

Pete A. Meyers

Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer

Adrian J. Hepner

Executive Vice President, Chief Medical Officer

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

4.960

2017

4.340

2018

3.870

2019(E)

2.985
Price To Earnings (TTM)
21.59
Price To Sales (TTM)
3.95
Price To Book (MRQ)
4.90
Price To Cash Flow (TTM)
18.26
Total Debt To Equity (MRQ)
23.68
LT Debt To Equity (MRQ)
20.78
Return on Investment (TTM)
19.41
Return on Equity (TTM)
15.81

Latest News

Latest News

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING Source text: (http://bit.ly/2En48mt) Further company coverage:

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2AG5uGB) Further company coverage:

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

BRIEF-EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY

* EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited

BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

* EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

BRIEF-Park West Asset Management reports 5.2 percent passive stake in Eagle Pharmaceuticals as on Aug 14, 2017

* Park West Asset Management LLC reports 5.2 percent passive stake in Eagle Pharmaceuticals Inc as on August 14, 2017 - SEC filing Source text : (http://bit.ly/2w8Kgk2) Further company coverage:

BRIEF-Eagle Pharmaceuticals posts Q2 adj. earnings $0.49/shr

* Eagle Pharmaceuticals Inc reports second quarter 2017 results

FDA rejects Eagle Pharmaceuticals' heat stroke treatment

Eagle Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex to treat heat stroke and requested an additional clinical trial, sending its shares down 20 percent.

REFILE-FDA rejects Eagle Pharmaceuticals' heat stroke treatment

Eagle Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex to treat heat stroke and requested an additional clinical trial.

BRIEF-Eagle Pharmaceuticals gets complete response letter from FDA on Ryanodex

* Eagle pharmaceuticals receives complete response letter from FDA on Ryanodex for exertional heat stroke application

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up